ArticleFrontiers in oncology2026
A study on the temporal patterns, anatomical distribution, and influencing factors of radiation therapy-associated second primary cancers in gynecological malignancies.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically analyze the clinical characteristics of post-radiotherapy secondary primary cancers (SPC) after treatment for gynecological malignancies, with the aim of informing and optimizing tumor management strategies. Methods: A retrospective collection of clinical data for 36 patients with gynecological malignancies who underwent radiotherapy at our hospital from January 2004 to December 2021. Results: The first primary cancer was predominantly cervical cancer (31 cases, 86.1%), with endometrial cancer accounting for 5 cases. Radiotherapy-related variables included the median radiotherapy duration of 42.5 days, external irradiation dose of 49.375 Gy, and total dose of 69.5 Gy; FIGO stages I/II/III were 7/18/11; lymph node metastasis in 6 cases; HPV positive in 20 cases; surgical history in 18 cases and chemotherapy history in 30 cases. The SPC cohort had a median onset age of 58 years and a median interval of 8 years after radiotherapy, with primary sites mostly in the rectum/colon and uterus; 24 cases occurred outside the radiotherapy field. Surgical, radiotherapy, and chemotherapy histories all influenced the timing and site of SPC. The median onset age after radiotherapy and interval to SPC were significantly longer in the cervical cancer group than in the endometrial cancer group (P = 0.01), and most SPC occurred within 5-10 years. Conclusions: The pathological features and treatment history of the initial cancer were associated with the timing and location of SPC. Analyses of post-radiotherapy SPC characteristics provide a scientific basis for optimizing clinical management and reducing SPC risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.